Amicus Therapeutics, Inc.

Amicus Therapeutics Misses on EPS, Stock Down 8.35%

Amicus Therapeutics reported a larger-than-expected loss per share, which likely contributed to the stock's decline of 8.35% following the earnings announcement. The lack of revenue information and management commentary adds uncertainty about the company's current performance and future outlook. Investors may be cautious as they await more detailed information in future reports.